2021
Hepatic Radiofrequency Ablation
Collettini F, Brangsch J, Reimann C, Chapiro J, Savic LJ, Buchholz R, Keller S, Hamm B, Goldberg SN, Makowski MR. Hepatic Radiofrequency Ablation. Investigative Radiology 2021, 56: 591-598. PMID: 33787536, DOI: 10.1097/rli.0000000000000777.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCatheter AblationDisease Models, AnimalMacrophagesMagnetic Resonance ImagingRabbitsRadiofrequency AblationElastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model
Collettini F, Reimann C, Brangsch J, Chapiro J, Savic LJ, Onthank DC, Robinson SP, Karst U, Buchholz R, Keller S, Hamm B, Goldberg SN, Makowski MR. Elastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model. Scientific Reports 2021, 11: 6814. PMID: 33767303, PMCID: PMC7994448, DOI: 10.1038/s41598-021-86417-6.Peer-Reviewed Original Research
2019
Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model
van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019, 9: 3674-3686. PMID: 31281506, PMCID: PMC6587357, DOI: 10.7150/thno.32943.Peer-Reviewed Original ResearchConceptsOil Red OPerfusion indexMicrovascular densityLipiodol depositionLiver cancerTherapeutic efficacyVX2 tumorsContrast-enhanced CT scanRabbit liver tumor modelTumor-specific functionsNon-tumoral liverLiver tumor modelRadiological-pathological correlationVX2 rabbit liver tumor modelPortal flowTransarterial chemoembolizationLeft lobeLipiodol retentionTherapeutic managementPatient responseTumor vascularityTumor volumeArterial flowCT scanTumor perfusion
2018
Science to Practice: Decrypting the Enigma of Ablation-induced Off-Target Effects-Is Network Pathway Analysis the Final Piece of the Puzzle?
Murali N, Laage-Gaupp FM, Chapiro J, Geschwind JF. Science to Practice: Decrypting the Enigma of Ablation-induced Off-Target Effects-Is Network Pathway Analysis the Final Piece of the Puzzle? Radiology 2018, 286: 405-408. PMID: 29356646, DOI: 10.1148/radiol.2017171779.Peer-Reviewed Original Research
2017
Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer
Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart CP, Geschwind JF. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. Clinical Cancer Research 2017, 23: 536-548. PMID: 27440271, PMCID: PMC5241187, DOI: 10.1158/1078-0432.ccr-16-0725.Peer-Reviewed Original Research
2014
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Chapiro J, Sur S, Savic LJ, Ganapathy-Kanniappan S, Reyes J, Duran R, Thiruganasambandam SC, Moats CR, Lin M, Luo W, Tran PT, Herman JM, Semenza GL, Ewald AJ, Vogelstein B, Geschwind JF. Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer. Clinical Cancer Research 2014, 20: 6406-6417. PMID: 25326230, PMCID: PMC4300523, DOI: 10.1158/1078-0432.ccr-14-1271.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaSuit-2 cell lineOrthotopic xenograft mouse modelBioluminescence imagingFavorable toxicity profileSublethal drug concentrationsAnti-invasive effectsXenograft mouse modelPDAC cell linesCell linesXenograft tumor modelHalf maximal inhibitory concentrationStrong anticancer effectsPancreatic cancerClinical trialsDuctal adenocarcinomaMouse modelToxicity profileIC50 profileTherapeutic efficacyMatrigel invasionVivo efficacyBLI signalMatrigel assaysMiaPaCa-2